Amgen said Tuesday night that its KRAS-targeted cancer drug AMG 510 is showing broader tumor-killing activity than previously reported. A new clinical trial intended to support the drug’s first approval in lung cancer is about to start enrolling patients — earlier than anticipated.
AMG 510 is the most important drug in Amgen’s research pipeline, potentially delivering billions of dollars in new revenue.
About the Author Reprints
